Loading...
RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.
Highlights

A collection of news and information related to Roche Holding AG published by this site and its partners.

Sort By: Relevancy | Date | Type
Displaying items 1-12 of 34
» View courant.com items only
    May 24, 2013 |Story| Reuters
  1. Wall Street posts first weekly loss since mid-April on Fed angst

    NEW YORK (Reuters) - The S&P 500 declined for a third day on Friday, with the three major stock indexes posting their first negative week since mid-April on lingering concern that the central bank may scale back its stimulus measures to support the economy.
    Reuters
    NEW YORK (Reuters) - The S&P 500 declined for a third day on Friday, with the three major stock indexes posting their first negative week since mid-April on lingering concern that the central bank may scale back its stimulus measures to support the...

    Tags: priceline.com Inc., BlackBerry, Level 3 Communications Incorporated, Fossil Incorporated, Websense Incorporated

  2. May 22, 2013 |Story| Reuters
  3. Inmunoterapia contra el cáncer podría ser un mercado de 35.000 mln dlrs anuales

    Reuters
    Por Ben Hirschler LONDRES, 22 may (Reuters) - Una nueva ola de medicinas que emplea el poder del sistema inmunológico para luchar contra el cáncer podría convertirse en el mayor grupo de medicamentos de la historia, con ventas potenciales de 35.000...

    Tags: Amgen Inc., Novartis AG, AstraZeneca Plc, Merck & Company Incorporated, Bristol Myers Squibb Company

  4. May 22, 2013 |Story| Reuters
  5. Immune system cancer drugs tipped to be a $35 billion market

    Reuters
    LONDON (Reuters) - A new wave of medicines that tap the power of the immune system to fight cancer could become the biggest drug class in history, with potential sales of $35 billion a year. That bullish sales forecast by analysts at U.S. bank...

    Tags: Health Treatments, Amgen Inc., AstraZeneca Plc, Vaccines, Food and Drug Administration

  6. May 22, 2013 |Story| Reuters
  7. Immune system cancer drugs tipped to be a $35 bln market

    Reuters
    * Potential sales of $35 bln a year over next 10 years - Citigroup * Immunotherapy may be used in up to 60 percent of cancers * Bristol-Myers Squibb and Roche both upgraded to "buy" By Ben Hirschler LONDON, May 22 (Reuters) - A new wave of medicines...

    Tags: Health Treatments, Amgen Inc., AstraZeneca Plc, Vaccines, Food and Drug Administration

  8. May 21, 2013 |Story| Reuters
  9. Market Chatter-Corporate finance press digest

    Reuters
    May 22 (Reuters) - The following corporate finance-related stories were reported by media on Wednesday: * Australia's Westfield Group is in talks to sell seven U.S. shopping malls to private real estate investment company Starwood Capital Group for more...

    Tags: Real Estate Buyers, Finance, Sigma-Aldrich Corporation, Pakistan, Automotive Equipment

  10. May 21, 2013 |Story| Reuters
  11. Roche, Sigma teamed up for failed Life Technologies bid -sources

    Reuters
    By Soyoung Kim and Greg Roumeliotis NEW YORK, May 21 (Reuters) - Roche Holding AG teamed up with Sigma-Aldrich Corp to make an unsuccessful bid for Life Technologies Corp earlier this year, people familiar with the matter said. Life Tech, the genetic...

    Tags: Medical Research, Sigma-Aldrich Corporation, Illumina, Inc.

  12. May 20, 2013 |Story| Reuters
  13. Pfizer halts study of lymphoma drug unlikely to help survival

    Reuters
    (Reuters) - Pfizer Inc, which has been on a hot streak with three recent approvals of cancer drugs, stumbled on Monday, saying it was halting a late-stage trial of a drug for aggressive non-Hodgkin lymphoma after independent monitors found it was not...

    Tags: Biotechnology, Hodgkin's Lymphoma, Health Treatments, Food and Drug Administration, Lymphoma

  14. May 16, 2013 |Story| Reuters
  15. CORRECTED-Data show new Roche leukemia drug may improve on Rituxan

    Reuters
    (Corrects paragraph 12 to show Biogen has stake in new drug) By Bill Berkrot May 15 (Reuters) - An experimental leukemia treatment that Roche Holding AG hopes will improve upon its best-selling cancer drug Rituxan delayed disease progression twice as...

    Tags: Biotechnology, Diseases and Illnesses, Health Treatments, Heart Disease, Biogen Idec Incorporated

  16. May 15, 2013 |Story| Reuters
  17. RPT-Market Chatter-Corporate finance press digest

    Reuters
    May 16 (Reuters) - The following corporate finance-related stories were reported by media on Thursday: * Dish Network Corp has lined up four banks to finance its $25.5 billion bid for Sprint Nextel Corp, escalating the bidding war against Japanese...

    Tags: Finance, Banking, Italy, Cubist Pharmaceuticals Incorporated, Sprint Nextel Corporation

  18. May 15, 2013 |Story| Reuters
  19. New cancer tools allow patients to reconsider chemo

    LOS ANGELES (Reuters) - After decades of using one-size-fits-all therapies to combat cancer, doctors are using new tools to help decide when their patients can skip chemotherapy or other harsh treatments.
    Reuters
    LOS ANGELES (Reuters) - After decades of using one-size-fits-all therapies to combat cancer, doctors are using new tools to help decide when their patients can skip chemotherapy or other harsh treatments. An approach to oncology that has been in place...

    Tags: Hodgkin's Lymphoma, Washington Hospital Center, Durham (Durham, North Carolina), Lymphoma, IMS Health Incorporated

  20. May 15, 2013 |Story| Reuters
  21. EXCLUSIVE-Roche exploring sale of diabetes device unit

    Reuters
    By Jessica Toonkel NEW YORK, May 15 (Reuters) - Swiss drugmaker Roche Holding AG is exploring a sale of its blood glucose meters business, three people familiar with the matter told Reuters on Wednesday, as the industry grapples with increased...

    Tags: Germany, Medtronic Incorporated, Bayer AG, Government Health Care, Diabetes

  22. May 12, 2013 |Story| Los Angeles Times
  23. Bill would regulate 'biosimilar' drugs

    SACRAMENTO — Two of the nation's largest biotech companies — Amgen Inc. of Thousand Oaks and Genentech Inc. of South San Francisco — are fighting in Sacramento to keep a tight grip on some of their most lucrative drugs.
    SACRAMENTO — Two of the nation's largest biotech companies — Amgen Inc. of Thousand Oaks and Genentech Inc. of South San Francisco — are fighting in Sacramento to keep a tight grip on some of their most lucrative drugs. At stake is a...

    Tags: U.S. Senate Committee on Appropriations, Jerry Hill, Chemical Industry, Pharmaceuticals, Genentech Inc.

 1  2 3Next >
Original site for Roche Holding AG topic gallery.